Open

Phase 1/1b study for people with advanced or metastatic cancer

In this study, we want to learn more about the safety and effectiveness of a drug called JANX008 in people with advanced or metastatic cancer. This is a study for people with non-small cell lung cancer, squamous cell carcinoma of the head and neck, colorectal cancer, or renal cell carcinoma.

Age & Gender

18 years ~ 99 years
Male, Female

Visit Availability

Standard business hours (M-F, 8-5)

Location

United States (Nationwide)

What will be asked of you

At each visit, you will receive the study drug via an IV. You will also be asked to complete various questionnaires, complete vitals, and discuss your well-being during visits.

Incentives

Study Mediciation

Total length of participation:
Until disease progression

Looking for Specific Volunteers

Able to participate:

You have adequate bone marrow, kidney, liver, and lung function.
Patients who have no standard treatment options available

Not eligible if:

Active brain or leptomeningeal metastasis.
Radiation therapy with treatment intent within the past 28 days
Major surgery within 28 days of enrollment
Active, uncontrolled bacterial, fungal, or viral infection

Contact the Team

Visit Location

Contact & Visit Location

Primary Contact

Lineberger Clinical Research
cancerclinicaltrials@med.unc.edu
(919) 966-4432

Primary Visit Location

NC Cancer Hospital (Basnight)
UNC Hospitals / UNC Medical Center
101 Manning Dr, Chapel Hill, NC 27514, USA

Additional Study Information

Principal Investigator

Jared Weiss
LCCC - Clinical Trials

Study Type

Clinical or Medical
Interventional

Study Topics

Cancer (Phase 1 Trials (all cancers))

IRB Number

23-1044

ClinicalTrials.gov

NCT05652686

Copyright © 2013-2022 The NC TraCS Institute, the integrated home of the NIH Clinical and Translational Science Awards (CTSA) Program at UNC-CH. This website is made possible by CTSA Grant UL1TR002489 and the National Center for Advancing Translational Sciences.

Helpful Links

Questions?

This email address is being protected from spambots. You need JavaScript enabled to view it.